CYP17 inhibitors--abiraterone, C17,20-lyase inhibitors and multi-targeting agents.
about
Molecular mechanisms underlying resistance to androgen deprivation therapy in prostate cancerTherapeutic Rationales, Progresses, Failures, and Future Directions for Advanced Prostate CancerRecent progress in pharmaceutical therapies for castration-resistant prostate cancerPromising Tools in Prostate Cancer Research: Selective Non-Steroidal Cytochrome P450 17A1 InhibitorsHedgehog Proteins Consume Steroidal CYP17A1 Antagonists: Potential Therapeutic Significance in Advanced Prostate CancerEnzymatic and Nonenzymatic Electrochemical Interaction of Abiraterone (Antiprostate Cancer Drug) with Multiwalled Carbon Nanotube BioelectrodesThe hunt for a selective 17,20 lyase inhibitor; learning lessons from nature.Androgen receptor targeting drugs in castration-resistant prostate cancer and mechanisms of resistanceLow β₂-adrenergic receptor level may promote development of castration resistant prostate cancer and altered steroid metabolism.Novel functionalized 5-(phenoxymethyl)-1,3-dioxane analogs exhibiting cytochrome P450 inhibition: a patent evaluation WO2015048311 (A1)Mechanisms of acquired resistance to androgen receptor targeting drugs in castration-resistant prostate cancer.Clinical implications for a treatment algorithm and differential indication to hormone therapy and chemotherapy options in metastatic castrate-resistant prostate cancer: a personal view.Therapeutic compounds for Cushing's syndrome: a patent review (2012-2016).Androgen receptor antagonism drives cytochrome P450 17A1 inhibitor efficacy in prostate cancerInhibition of Plk1 represses androgen signaling pathway in castration-resistant prostate cancer.STAT3 and STAT5A are potential therapeutic targets in castration-resistant prostate cancer.Luteinizing Hormone-Releasing Hormone Agonists are Superior to Subcapsular Orchiectomy in Lowering Testosterone Levels of Men with Prostate Cancer: Results from a Randomized Clinical Trial.TSPYL Family Regulates CYP17A1 and CYP3A4 Expression: Potential Mechanism Contributing to Abiraterone Response in Metastatic Castration-Resistant Prostate Cancer.Simultaneous quantitation of nine hydroxy-androgens and their conjugates in human serum by stable isotope dilution liquid chromatography electrospray ionization tandem mass spectrometry.Kinetic processivity of the two-step oxidations of progesterone and pregnenolone to androgens by human cytochrome P450 17A1.Structure-based optimisation of non-steroidal cytochrome P450 17A1 inhibitors.Effect of dutasteride on castration-resistant prostate cancer.Novel small molecule guanidine Sigma1 inhibitors for advanced prostate cancer.Steroidogenic Metabolism of Galeterone Reveals a Diversity of Biochemical Activities.Molecular and cellular mechanisms of castration resistant prostate cancer.Structural and Functional Evaluation of Clinically Relevant Inhibitors of Steroidogenic Cytochrome P450 17A1.Human Cytochrome CYP17A1: The Structural Basis for Compromised Lyase Activity with 17-HydroxyprogesteroneDown-regulation of AR splice variants through XPO1 suppression contributes to the inhibition of prostate cancer progression
P2860
Q26739708-B015F9D5-A1EA-497E-AADD-D3DAF19CBB4EQ26750620-123F2CF1-4D61-4EF7-8611-F630E2BC21C4Q27022567-13B40B94-BAA4-494F-B4B2-3AA8178B1C74Q28277042-E6DE24B4-424D-4FD6-A952-5685C3E63C0CQ28277254-4A3D4190-184F-46D6-AA26-A4B704C51D0CQ28818516-0A79BCD8-6A85-47F7-B0C2-69D4058C835AQ34525556-1EE67E4A-4D06-4D79-A4A1-9735ED698035Q36470627-B15FEC95-8F7C-4286-B2C2-F14B649FC878Q36738996-4EC11EA6-B887-411E-8769-1002BA50B912Q36997189-221795C6-B897-438B-9E05-7EC3EBDDB279Q38220073-D8AE05AE-F8D6-47F0-839A-D28896919FEAQ38263563-B070A706-0201-4E93-B8F9-F05DAD212292Q38907424-BB61AA3E-70A5-41EE-B0C3-BB7B2FC6711CQ42188589-42BD4F36-D8B3-421F-B58B-6AA2C758527EQ43211192-DC9BAC29-3D6E-4851-9A1D-FA1B81ECDE30Q47110097-4D96C9F0-6C10-4752-A082-F2731776623AQ47610526-37E2BF5A-908E-4B3B-992E-1247155B3537Q47659136-EDC8C13A-9334-4A3D-8346-0FE1389A03E7Q48022094-B9C26C91-3407-40ED-BBE4-AF290A11AE2BQ48164914-DDCD184E-95AA-44F9-B030-9DD104AB74FFQ48185348-5032B35C-C892-45E3-9523-AF15685CD774Q49368361-4E1639FE-63A2-4A05-ADC9-74E019CDD1B7Q50744719-5457EB7C-54AA-4048-A01E-C7B9E0BAA7D9Q50925353-A7D1C4D1-84A6-4EAC-9ACC-22E07F5D3E2FQ52608488-08B0191F-555E-41F5-847E-83BA026882C9Q55262957-970094F2-2401-40A0-820A-F2FD0F479F59Q57142928-604EA261-2D4F-4FF1-8442-C17060BEF748Q59132279-C072D08C-4467-45A8-813D-7CAAE594B720
P2860
CYP17 inhibitors--abiraterone, C17,20-lyase inhibitors and multi-targeting agents.
description
2013 nî lūn-bûn
@nan
2013 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
CYP17 inhibitors--abiraterone, C17,20-lyase inhibitors and multi-targeting agents.
@ast
CYP17 inhibitors--abiraterone, C17,20-lyase inhibitors and multi-targeting agents.
@en
CYP17 inhibitors--abiraterone, C17,20-lyase inhibitors and multi-targeting agents.
@nl
type
label
CYP17 inhibitors--abiraterone, C17,20-lyase inhibitors and multi-targeting agents.
@ast
CYP17 inhibitors--abiraterone, C17,20-lyase inhibitors and multi-targeting agents.
@en
CYP17 inhibitors--abiraterone, C17,20-lyase inhibitors and multi-targeting agents.
@nl
prefLabel
CYP17 inhibitors--abiraterone, C17,20-lyase inhibitors and multi-targeting agents.
@ast
CYP17 inhibitors--abiraterone, C17,20-lyase inhibitors and multi-targeting agents.
@en
CYP17 inhibitors--abiraterone, C17,20-lyase inhibitors and multi-targeting agents.
@nl
P2860
P356
P1476
CYP17 inhibitors--abiraterone, C17,20-lyase inhibitors and multi-targeting agents.
@en
P2093
Qingzhong Hu
P2860
P2888
P356
10.1038/NRUROL.2013.274
P407
P577
2013-11-26T00:00:00Z
P5875
P6179
1034692836